GE HealthCare (Nasdaq:GEHC) announced that its MIM Software unit began rolling out its new MIM Symphony HDR Prostate solution.
MIM Symphony HDR supports high dose-rate (HDR) brachytherapy with direct tumor visualization from MRI scans during live ultrasound procedures for HDR prostate treatments. The technology corrects MRI orientation and offers MRI guidance during HDR prostate procedures. It aims to increase clinician confidence and help improve patient outcomes.
HDR brachytherapy, a prostate cancer treatment, involves implanting radioactive sources into the prostate gland via needles. Clinicians typically use computed tomography (CT) or ultrasound for planning these procedures. Using MRI can reduce toxicity to critical structures, GE HealthCare said in a news release. However, the challenge of accurately aligning MRI contours with live ultrasound hinders the use of MRI in HDR treatments.
MIM Symphony HDR aligns contours on preoperatively acquired MRI with live ultrasound. It provides clear visibility of the prostate, lesions and critical structures.
This new solution adds to GE HealthCare’s MIM Software portfolio of vendor-neutral solutions for radiation oncology. The company brought the software into its portfolio through an acquisition of MIM Software in April.
“Our goal with this solution is to empower clinicians to plan and deliver safe, more informed, and precise treatment for patients with prostate disease,” said Andrew Nelson, CEO of MIM Software, GE HealthCare. “MIM Symphony HDR Prostate exemplifies decades of MIM Software and GE HealthCare innovations that enable precision care, and we’re thrilled to expand our impact in brachytherapy.”
